Vamorolone 0.25 mg/day/day ( DrugBank: Vamorolone )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
113	筋ジストロフィー	2

113. 筋ジストロフィー

---

臨床試験数 : 622 /  薬物数 : 485 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03038399 (ClinicalTrials.gov)	February 2, 2017	30/1/2017	Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)	A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)	Duchenne Muscular Dystrophy	Drug: Vamorolone 0.25 mg/day/day;Drug: Vamorolone 0.75 mg/day/day;Drug: Vamorolone 2.0 mg/day/day;Drug: Vamorolone 6.0 mg/day/day	ReveraGen BioPharma, Inc.	University of Pittsburgh;Cooperative International Neuromuscular Research Group	Completed	4 Years	7 Years	Male	46	Phase 2	United States;Australia;Canada;Israel;Sweden;United Kingdom
2	NCT02760277 (ClinicalTrials.gov)	July 28, 2016	28/4/2016	An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)	A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)	Duchenne Muscular Dystrophy	Drug: Vamorolone 0.25 mg/day/day;Drug: Vamorolone 0.75 mg/day/day;Drug: Vamorolone 2.0 mg/day/day;Drug: Vamorolone 6.0 mg/day/day	ReveraGen BioPharma, Inc.	University of Pittsburgh;National Institute of Neurological Disorders and Stroke (NINDS);Cooperative International Neuromuscular Research Group;National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	4 Years	7 Years	Male	48	Phase 2	United States;Australia;Canada;Israel;Sweden;United Kingdom